<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40605149</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>A Nearly 50% Risk of MACCE Cutdown by Personalized Antiplatelet Therapy: The Subgroup Analysis of Hypertension in PATH-PCI Trial.</ArticleTitle><Pagination><StartPage>1723</StartPage><EndPage>1731</EndPage><MedlinePgn>1723-1731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.31692</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individualized antiplatelet therapy has been gradually chosen by more and more (percutaneous coronary intervention) PCI patients. Hypertension, as an important risk factor for a variety of adverse outcomes after PCI, has been found in many studies. Therefore, we are interested in whether patients who undergo PCI have a different benefit from individualized antiplatelet therapy when they have hypertension.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of individualized treatment in PCI patients with or without hypertension.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two thousand two hundred and thirty-seven chronic coronary syndrome patients from PATH-PCI study were randomly assigned to receive either personalized antiplatelet therapy group or standard antiplatelet therapy group. Then sub-analysis were conducted to estimate the results of clinical outcomes after 180 days follow-up between hypertension or non-hypertension across the two treatment groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the standard treatment group, patients with hypertension who received individualized treatment had fewer adverse events. The MACCE incidences were (21 [3.3%] vs. 37 [5.8%], p&#x2009;=&#x2009;0.038), MACE incidences was (14 [2.2%] vs. 28 [4.4%], p&#x2009;=&#x2009;0.033), ST incidences was (2 [0.3%] vs. 10 [1.6%], p&#x2009;=&#x2009;0.038), and TVR incidences was (1 [0.2%] vs. 8 [1.2%], p&#x2009;=&#x2009;0.038). Within patients without hypertensive, after individualized therapy, there were also less NACE (25 [5.1%] vs. 39 [8.3%], p&#x2009;=&#x2009;0.045), MACCE (14 [2.8%] vs. 33 [7.0%], p&#x2009;=&#x2009;0.003), MACE (11 [2.2%] vs. 24 [5.1%], p&#x2009;=&#x2009;0.017), and Re-MI incidences (7 [1.4%] vs. 17 [3.6%], p&#x2009;=&#x2009;0.029) recorded. After multivariable Cox analyses, individualized treatment had a significant protective effect against MACE (HR&#x2009;=&#x2009;0.48, 95% CI 0.25-0.92, p&#x2009;=&#x2009;0.028), MACCE (HR&#x2009;=&#x2009;0.55, 95% CI 0.32-0.94, p&#x2009;=&#x2009;0.029), and ST (HR&#x2009;=&#x2009;0.18, 95% CI 0.04-0.85, p&#x2009;=&#x2009;0.030) in hypertensive patients. Besides, there were certain protective effects on reducing MACE (HR&#x2009;=&#x2009;0.43, 95% CI 0.21-0.89, p&#x2009;=&#x2009;0.023), MACCE (HR&#x2009;=&#x2009;0.41, 95% CI 0.22-0.77, p&#x2009;=&#x2009;0.005), and Re-MI (HR&#x2009;=&#x2009;0.37, 95% CI 0.15-0.91, p&#x2009;=&#x2009;0.029) incidences in non-hypertensive patients with personalized antiplatelet therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Individualized treatment can provided multiple protective effects, which significant decreasing the MACCE and MACE incidences in all CCS patients after PCI without increasing the risk of bleeding compared with standard therapy. Beside, a protective effect against stent thrombosis in hypertension and against Re-MI incidence in non-hypertension were obvious.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The details of the design were registered on http://www.chictr.org.cn&#xa0;(Identifier: ChiCTR-INR-16010077).</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ting-Ting</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High Incidence Disease Research in Xingjiang (Xinjiang Medical University, Ministry of Education), Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Hypertension Research of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ying-Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High Incidence Disease Research in Xingjiang (Xinjiang Medical University, Ministry of Education), Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhi-Long</ForeName><Initials>ZL</Initials><Identifier Source="ORCID">0000-0003-3185-1513</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Chang-Jiang</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0009-0008-5813-5940</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Xian-Geng</ForeName><Initials>XG</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Hypertension Research of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yi-Tong</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High Incidence Disease Research in Xingjiang (Xinjiang Medical University, Ministry of Education), Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0632-4626</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High Incidence Disease Research in Xingjiang (Xinjiang Medical University, Ministry of Education), Urumqi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Hypertension Research of Xinjiang Medical University, Urumqi, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>This work was supported by the Key research and development projects of Xinjiang Province, China (2022B03022-5) and Xinjiang Science and Technology, Tian Shan Yingcai Lingjun Project (2022TSYCLJ0029).</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bleeding</Keyword><Keyword MajorTopicYN="N">high platelet reactivity</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">individualized antiplatelet therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40605149</ArticleId><ArticleId IdType="doi">10.1002/ccd.31692</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. J. Neumann, M. Sousa&#x2010;Uva, A. Ahlsson, et al., &#x201c;2018 ESC/EACTS Guidelines on Myocardial Revascularization,&#x201d; European Heart Journal 40, no. 2 (January 2019): 87&#x2013;165, https://doi.org/10.1093/eurheartj/ehy394.</Citation></Reference><Reference><Citation>J. P. Collet, H. Thiele, E. Barbato, et al., &#x201c;2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST&#x2010;Segment Elevation,&#x201d; European Heart Journal 42, no. 14 (April 2021): 1289&#x2013;1367, https://doi.org/10.1093/eurheartj/ehaa575.</Citation></Reference><Reference><Citation>A. K. Malakar, D. Choudhury, B. Halder, P. Paul, A. Uddin, and S. Chakraborty, &#x201c;A Review on Coronary Artery Disease, Its Risk Factors, and Therapeutics,&#x201d; Journal of Cellular Physiology 234, no. 10 (August 2019): 16812&#x2013;16823, https://doi.org/10.1002/jcp.28350.</Citation></Reference><Reference><Citation>S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, Prospective Studies Collaboration,Age&#x2010;Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta&#x2010;Analysis of Individual Data For One Million Adults in 61 Prospective Studies,&#x201d; Lancet 360, no. 9349 (2002): 1903&#x2013;1913, https://doi.org/10.1016/s0140-6736(02)11911-8.</Citation></Reference><Reference><Citation>B. Lacey, S. Lewington, R. Clarke, et al., &#x201c;Age&#x2010;Specific Association Between Blood Pressure and Vascular and Non&#x2010;Vascular Chronic Diseases in 0.5 Million Adults in China: A Prospective Cohort Study,&#x201d; Lancet Global Health 6, no. 6 (June 2018): e641&#x2013;e649, https://doi.org/10.1016/S2214-109X(18)30217-1.</Citation></Reference><Reference><Citation>M. Sajadian, L. Alizadeh, M. Ganjifard, A. Mardani, M. A. Ansari, and H. Falsoleiman, &#x201c;Factors Affecting In&#x2010;Stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty,&#x201d; Galen Medical Journal 7 (June 2018): e961, https://doi.org/10.22086/gmj.v0i0.961.</Citation></Reference><Reference><Citation>J. Zhang, Q. Zhang, K. Zhao, Y. J. Bian, Y. Liu, and Y. T. Xue, &#x201c;Risk Factors for In&#x2010;Stent Restenosis After Coronary Stent Implantation in Patients With Coronary Artery Disease: A Retrospective Observational Study,&#x201d; Medicine 101, no. 47 (November 2022): e31707, https://doi.org/10.1097/MD.0000000000031707.</Citation></Reference><Reference><Citation>P. Wang, H. Qiao, R. Wang, R. Hou, and J. Guo, &#x201c;The Characteristics and Risk Factors of In&#x2010;Stent Restenosis in Patients With Percutaneous Coronary Intervention: What Can We Do,&#x201d; BMC Cardiovascular Disorders 20, no. 1 (December 2020): 510, https://doi.org/10.1186/s12872-020-01798-2.</Citation></Reference><Reference><Citation>D. M. Alexandrescu, O. Mitu, I. Costache, et al., &#x201c;Risk Factors Associated With Intra&#x2010;Stent Restenosis After Percutaneous Coronary Intervention,&#x201d; Experimental and Therapeutic Medicine 22, no. 4 (October 2021): 1141, https://doi.org/10.3892/etm.2021.10575.</Citation></Reference><Reference><Citation>B. Redfors, S. Chen, O. Ben&#x2010;Yehuda, et al., &#x201c;Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT&#x2010;DES Study),&#x201d; American Journal of Cardiology 124, no. 9 (November 2019): 1380&#x2013;1388, https://doi.org/10.1016/j.amjcard.2019.07.044.</Citation></Reference><Reference><Citation>P. K. Bundhun, Z. J. Wu, and M. H. Chen, &#x201c;Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta&#x2010;Analysis of 100 Studies,&#x201d; Medicine 94, no. 50 (December 2015): e2313, https://doi.org/10.1097/MD.0000000000002313.</Citation></Reference><Reference><Citation>M. Lingman, P. Albertsson, J. Herlitz, L. Bergfeldt, and B. Lagerqvist, &#x201c;The Impact of Hypertension and Diabetes on Outcome in Patients Undergoing Percutaneous Coronary Intervention,&#x201d; American Journal of Medicine 124, no. 3 (March 2011): 265&#x2013;275, https://doi.org/10.1016/j.amjmed.2010.09.015.</Citation></Reference><Reference><Citation>D. W. Park, Y. H. Kim, S. C. Yun, et al., &#x201c;Frequency, Causes, Predictors, and Clinical Significance of Peri&#x2010;Procedural Myocardial Infarction Following Percutaneous Coronary Intervention,&#x201d; European Heart Journal 34, no. 22 (June 2013): 1662&#x2013;1669, https://doi.org/10.1093/eurheartj/eht048.</Citation></Reference><Reference><Citation>G. Ndrepepa, P. Groha, A. L. Lahmann, et al., &#x201c;Increased Bleeding Risk During Percutaneous Coronary Interventions by Arterial Hypertension,&#x201d; Catheterization and Cardiovascular Interventions 88, no. 2 (August 2016): 184&#x2013;190, https://doi.org/10.1002/ccd.26272.</Citation></Reference><Reference><Citation>P. H. Lee, S. Park, H. Nam, et al., &#x201c;Intracranial Bleeding After Percutaneous Coronary Intervention: Time&#x2010;Dependent Incidence, Predictors, and Impact on Mortality,&#x201d; Journal of the American Heart Association 10, no. 15 (August 2021): e019637, https://doi.org/10.1161/JAHA.120.019637.</Citation></Reference><Reference><Citation>H. Y. Wang, K. F. Dou, Y. Wang, D. Yin, B. Xu, and R. L. Gao, &#x201c;Benefit&#x2010;Risk Profile of DAPT Continuation Beyond 1 Year After PCI in Patients With High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline,&#x201d; Cardiovascular Drugs and Therapy 34, no. 5 (October 2020): 663&#x2013;675, https://doi.org/10.1007/s10557-020-07030-9.</Citation></Reference><Reference><Citation>X. Shi, Y. Zhang, Y. Zhang, et al., &#x201c;Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial,&#x201d; Frontiers in Cardiovascular Medicine 8 (June 2021): 676954, https://doi.org/10.3389/fcvm.2021.676954.</Citation></Reference><Reference><Citation>D. L. Shen, B. Wang, J. Bai, et al., &#x201c;Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population,&#x201d; Journal of Cardiovascular Pharmacology 67, no. 3 (March 2016): 232&#x2013;236, https://doi.org/10.1097/FJC.0000000000000337.</Citation></Reference><Reference><Citation>X. Wang, S. Wang, J. Yang, X. Yu, and L. Liu, &#x201c;Genotype&#x2010;Guided Antiplatelet Therapy Compared With Standard Therapy for Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Thrombosis Research 193 (September 2020): 130&#x2013;138, https://doi.org/10.1016/j.thromres.2020.06.002.</Citation></Reference><Reference><Citation>Y. Y. Zheng, T. T. Wu, Y. Yang, et al., &#x201c;Personalized Antiplatelet Therapy Guided by a Novel Detection of Platelet Aggregation Function in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Clinical Trial,&#x201d; European Heart Journal&#x2010;Cardiovascular Pharmacotherapy 6, no. 4 (July 2020): 211&#x2013;221, https://doi.org/10.1093/ehjcvp/pvz059.</Citation></Reference><Reference><Citation>L. S. Liu, &#x201c;Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. [2010 Chinese Guidelines for the Management of Hypertension],&#x201d; Zhonghua Xin Xue Guan Bing Za Zhi 39, no. 7 (July 2011): 579&#x2013;615.</Citation></Reference><Reference><Citation>Y. Li, C. Wang, Z. Feng, et al., &#x201c;Premature Coronary Heart Disease Complicated With Hypertension in Hospitalized Patients: Incidence, Risk Factors, Cardiovascular&#x2010;Related Comorbidities and Prognosis, 2008&#x2010;2018,&#x201d; International Journal of Cardiology: Cardiovascular Risk and Prevention 21 (March 2024): 200253, https://doi.org/10.1016/j.ijcrp.2024.200253.</Citation></Reference><Reference><Citation>T. Charpentier, C. Ferdynus, T. Lair, et al., &#x201c;Bleeding Risk of Ticagrelor Compared to Clopidogrel in Intensive Care Unit Patients With Acute Coronary Syndrome: A Propensity&#x2010;Score Matching Analysis,&#x201d; PLoS One 15, no. 5 (May 2020): e0232768, https://doi.org/10.1371/journal.pone.0232768.</Citation></Reference><Reference><Citation>D.&#x2010;W. Park, O. Kwon, J. S. Jang, et al., &#x201c;Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management,&#x201d; Circulation 140, no. 23 (2019): 1865&#x2013;1877, https://doi.org/10.1161/CIRCULATIONAHA.119.041766.</Citation></Reference><Reference><Citation>H. Tian, M. Qiu, K. Na, et al., &#x201c;Effect of CYP2C19 Genotype on Outcomes of Treatment With Ticagrelor Versus Clopidogrel in Acute Coronary Syndrome Patients With Diabetes Mellitus: A Analysis in a Large&#x2010;Scale, Real&#x2010;World Study,&#x201d; European Journal of Pharmacology 996 (March 2025): 177546, https://doi.org/10.1016/j.ejphar.2025.177546.</Citation></Reference><Reference><Citation>E. Cecchi, R. Marcucci, M. Chiostri, et al., &#x201c;Dual Antiplatelet Therapy Tailored on Platelet Function Test After Coronary Stent Implantation: A Real&#x2010;World Experience,&#x201d; Internal and Emergency Medicine 10, no. 7 (October 2015): 805&#x2013;814, https://doi.org/10.1007/s11739-015-1242-4.</Citation></Reference><Reference><Citation>T. C. Godschalk, L. M. Willemsen, B. Zwart, et al., &#x201c;Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis,&#x201d; American Journal of Cardiology 119, no. 10 (May 2017): 1500&#x2013;1506, https://doi.org/10.1016/j.amjcard.2017.02.033.</Citation></Reference><Reference><Citation>A. Komosa, J. M. Siller&#x2010;Matula, M. Lesiak, et al., &#x201c;Association Between High On&#x2010;Treatment Platelet Reactivity and Occurrence of Cerebral Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention,&#x201d; Thrombosis Research 138 (February 2016): 49&#x2013;54, https://doi.org/10.1016/j.thromres.2015.12.021.</Citation></Reference><Reference><Citation>S. Lim, S. J. Hong, J. H. Kim, et al., &#x201c;High Platelet Reactivity Strongly Predicts Early Stent Thrombosis in Patients With Drug&#x2010;ElutingStent Implantation,&#x201d; Scientific Reports 14 (2024): 520, https://doi.org/10.1038/s41598-023-50920-9.</Citation></Reference><Reference><Citation>M. Marketou, P. Spatharaki, E. Nioti, et al., &#x201c;Elevated Platelet Reactivity in Patients With Uncontrolled Hypertension: The Effect of CHA2DS2&#x2010;VASC Score,&#x201d; supplement, Journal of Hypertension 41, no. S3 (2023): e303, https://doi.org/10.1097/01.hjh.0000942160.75171.35.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>